Sonographic septation: a predictor of sequelae of tuberculous pleurisy after treatment

Y-F Lai,¹ M-C Su,² H-H Weng,³ J-T Wu,¹ C-T Chiu¹

ABSTRACT

Background: Findings in the literature have been quite conflicting with respect to predicting residual pleural thickening (RPT) in tuberculous pleurisy (TP). The aim of this study was to determine which sonographic feature of TP might help in predicting the development of RPT.

Methods: Eighty-seven patients with TP were enrolled prospectively. The initial sonographic features were classified as anechoic, homogenously echogenic, complex non-septated and complex septated. The RPT level was measured 12 months after the start of antituberculosis (TB) treatment. Spirometry was performed 6 and 12 months after the start of anti-TB treatment.

Results: A higher odds of an RPT level >10 mm was found in patients with positive TB bacillus culture in pleural fluid (OR, 20.9; 95% CI, 2.2 to 198.0) and a complex septated sonographic pattern (OR, 145.0; 95% CI, 22.3 to 942.3). A complex septated sonographic pattern can predict RPT with a sensitivity of 80%, specificity of 96%, positive predictive value of 84% and negative predictive value of 94%. Patients with an RPT level >10 mm had a lower forced vital capacity than those without (75.4% (9.2%) predicted vs 83.2% (9.5%) predicted, p<0.01)

Conclusion: A complex septated sonographic pattern is a useful sign to predict an RPT level >10 mm 1 year after the start of anti-TB treatment. An RPT level >10 mm is associated with a high probability of decreased lung volumes. Therefore, the initial sonographic feature is beneficial in predicting the sequelae of TP after treatment.

The incidence rate of tuberculosis (TB) in Taiwan was 67.38 per 100 000 people in 2006.¹ Although prevalence and mortality rates have decreased with time owing to effective drug treatment, this infectious disease remains a serious public health issue because of its detrimental complications. Tuberculous pleurisy (TP) is one of the manifestations of TB and is present in 10% of all causes of TB in Taiwan.² Although updated therapeutic regimens can effectively control this infectious disease and minimise its sequelae, residual pleural thickening (RPT) has been found in about half of the patients.³⁻⁵ We have previously shown that approximately 26% of patients with TP after treatment are complicated with RPT levels >10 mm.⁶ RPT may result in a decreased lung volume and then have important clinical repercussions. It is therefore important to identify the clinical and functional impairment resulting from RPT in patients with TP receiving anti-TB treatment. Thus, the aim of this prospective study was to investigate if sonographic features can serve as a predictor of patient outcomes 12 months after the start of anti-TB drug treatment. To the best of our knowledge, limited studies have been published regarding the evaluation of RPT and the associated impairment in treated TP patients by using the initial sonographic parameters.

METHODS

Patients

Between February 2004 and January 2007, all patients aged 17 years and older with the initial presentation of pleural effusion not treated elsewhere were eligible for this prospective study. Following thoracic sonography, all patients received a needle pleural biopsy and a diagnostic thoracentesis on the first day of hospitalisation for pleural effusion. Informed consent was obtained from all patients prior to the study. TP was confirmed by the presence of caseating granulomas either with or without acid-fast bacilli on histological examination. Other diseases such as sarcoidosis, rheumatoid arthritis, and fungal or nocardial infection which may produce granulomatous pleurisy were excluded.

Standard anti-TB treatment including isoniazid (300 mg/day), rifampin (450 mg/day in patients <50 kg body weight; 600 mg/day in patients ≥50 kg body weight), ethambutol (800 mg/day) and pyrazinamide (1500 mg/day) was given to the patients thereafter. With the exception of pyrazinamide which was administered during the initial 2 months only, all anti-TB drugs were administered for a total of 6 months. No patient had received pleural fluid drainage during the study period.

Chest x rays

Standard posterior–anterior and lateral chest radiographs of each patient were taken on admission and on a 2-monthly basis during the outpatient follow-up period up to 6 months after completion of the full treatment course. At initial presentation, the amount of pleural effusion on chest x ray was recorded as small (less than one-third of one hemithorax), moderate (between one-third and two-thirds of one hemithorax) or large (more than two-thirds of one hemithorax). Significant RPT was defined as the maximal pleural thickness in excess of 10 mm on posterior–anterior and lateral chest radiographs. Measurements were made by two independent observers and concurrence was evaluated by using the kappa index.

Pulmonary function tests

Standard spirometric tests were performed at 6 and 12 months after the beginning of anti-TB treatment (Vitalograph, Spirotac III, Vitalograph, Lenexa, Kansas, USA). All pulmonary function...
measurements were performed in accordance with the American Thoracic Society guidelines.  

Sonography

All patients were examined with a linear, convex and sector ultrasound transducer with a frequency of 3.5–5.0 MHz (model SSD 63, Aloka, Tokyo, Japan). According to the internal echogenicity, pleural effusions have been categorised into four types: anechoic, homogenously echogenic, complex non-septated and complex septated. Effusions induced by TB were subclassified as anechoic, complex non-septated or complex septated since the homogenously echogenic type had not been observed among patients with TP. Effusion was defined as anechogenic if totally echo-free spaces were present between the visceral and parietal pleura (fig 1A). Effusion was defined as complex if echogenic materials were present inside the effusion, and then subclassified into non-septated or septated according to the absence or presence of septa inside the effusions (fig 1B,C).

Statistical analysis

Data normality was assessed by using the Shapiro–Wilk test. Normally distributed numerical variables are presented as mean (SD), while median values with interquartile range (IQR, 25% and 75%) were expressed for the skewed data. Between-groups comparisons for continuous data were performed using the Student t test or Wilcoxon rank-sum test as appropriate. Independent proportions were compared by using the Fisher exact or $\chi^2$ test. We then performed a multiple logistics regression analysis by using a forward stepwise selection procedure to study the independent influences of these variables on the risk of RPT. Results of the logistic regression model were presented as the odds ratio (OR) and 95% CI. A $p$ value $<0.05$ was considered statistically significant. Statistical analyses were performed using commercially available software (SPSS version 12.0; SPSS, Chicago, Illinois, USA).

RESULTS

During the 3-year period, 92 consecutive patients with TP were diagnosed. Five were excluded because of non-adherence to the treatment or loss to follow-up. Among the 87 remaining patients, 61 were male, with a mean age of 64.2 (18.2) years. Two experienced readers, who were blinded to the clinical history, assessed the initial size of the pleural effusion and the initial and final pleural thickenings 12 months after the start of anti-TB treatment. The interobserver kappa index was 0.95, with the strength of agreement being considered very good when $\kappa = 0.8–1.0$.

The patient characteristics are shown in table 1. No pleural thickening was observed in the initial radiographic and sonographic studies. Men were found to be more likely to develop an RPT level $\geq 10$ mm after anti-TB treatment. The pleural fluid analytical variables are listed in table 2. There was no significant difference in the pleural fluid analysis between the two groups except for a higher lactate dehydrogenase (LDH) level in patients with RPT levels $>10$ mm. Table 3 shows the initial sonographic features of all TP patients. No patient presented the feature of a homogenously echogenic pattern.

Table 1  Patient characteristics with RPT $>10$ mm and $\leq 10$ mm

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>RPT $&gt; 10$ mm $(n = 20)$</th>
<th>RPT $\leq 10$ mm $(n = 67)$</th>
<th>$p$ Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male gender (%)</td>
<td>90.0</td>
<td>64.2</td>
<td>0.029</td>
</tr>
<tr>
<td>Age (years (SD))</td>
<td>61.2 (20.3)</td>
<td>65.1 (17.6)</td>
<td>0.345</td>
</tr>
<tr>
<td>Symptoms to treatment, days</td>
<td>11 (7–30)</td>
<td>10 (7–14)</td>
<td>0.620</td>
</tr>
<tr>
<td>Smokers (%)</td>
<td>55.0</td>
<td>34.3</td>
<td>0.096</td>
</tr>
<tr>
<td>Alcohol abuse (%)</td>
<td>15.0</td>
<td>9.0</td>
<td>0.424</td>
</tr>
<tr>
<td>Diabetes mellitus (%)</td>
<td>20.0</td>
<td>20.9</td>
<td>0.931</td>
</tr>
<tr>
<td>Pulmonary TB (%)</td>
<td>30.0</td>
<td>23.9</td>
<td>0.581</td>
</tr>
<tr>
<td>Initially large amount of pleural effusion (%)</td>
<td>65.0</td>
<td>40.3</td>
<td>0.148</td>
</tr>
<tr>
<td>Loculated pleural effusion (%)</td>
<td>20.0</td>
<td>16.4</td>
<td>0.740</td>
</tr>
<tr>
<td>Positive pleural biopsy culture (%)</td>
<td>25.0</td>
<td>31.3</td>
<td>0.782</td>
</tr>
<tr>
<td>Positive pleural fluid culture (%)</td>
<td>20.0</td>
<td>4.5</td>
<td>0.046</td>
</tr>
<tr>
<td>Sputum positive for AFB (%)</td>
<td>25.0</td>
<td>16.4</td>
<td>0.511</td>
</tr>
</tbody>
</table>

AFB, acid-fast bacillus; RPT, residual pleural thickening; TB, tuberculosis.
Table 2 Pleural fluid findings of patients with RPT &gt;10 mm and &lt;10 mm

<table>
<thead>
<tr>
<th>Pleural fluid analyses</th>
<th>RPT &gt;10 mm (n = 20)</th>
<th>RPT &lt;10 mm (n = 67)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphocyte (%)</td>
<td>89.5 (76.5–93.5)</td>
<td>88.0 (74.0–93.0)</td>
<td>0.956</td>
</tr>
<tr>
<td>Neutrophil (%)</td>
<td>10.0 (5.0–17.0)</td>
<td>8.0 (3.0–18.0)</td>
<td>0.479</td>
</tr>
<tr>
<td>Leucocytes (cells/mm³)</td>
<td>1732 (890–2647)</td>
<td>1960 (1000–3520)</td>
<td>0.139</td>
</tr>
<tr>
<td>LDH (U/l)</td>
<td>584 (290–682)</td>
<td>183 (127–399)</td>
<td>0.001</td>
</tr>
<tr>
<td>Protein (g/dl)</td>
<td>4.75 (4.25–5.45)</td>
<td>5.0 (4.40–5.40)</td>
<td>0.495</td>
</tr>
<tr>
<td>Glucose (mg/dl)</td>
<td>93 (43–132)</td>
<td>95 (78–114)</td>
<td>0.684</td>
</tr>
<tr>
<td>pH</td>
<td>7.20 (7.18–7.24)</td>
<td>7.21 (7.18–7.29)</td>
<td>0.126</td>
</tr>
<tr>
<td>CEA (ng/ml)</td>
<td>3.0 (2.0–3.7)</td>
<td>3.1 (2.4–3.5)</td>
<td>0.571</td>
</tr>
</tbody>
</table>

Data are expressed as median (25–75% range). CEA, carcinoembryonic antigen; LDH, lactate dehydrogenase; RPT, residual pleural thickening.

Table 3 Initial sonographic findings of patients with tuberculous pleurisy with RPT &gt;10 mm and &lt;10 mm

<table>
<thead>
<tr>
<th>Sonographic features</th>
<th>RPT &gt;10 mm (n = 20)</th>
<th>RPT &lt;10 mm (n = 67)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anechoic (%)</td>
<td>5.0</td>
<td>68.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Complex non-septated echoic (%)</td>
<td>15.0</td>
<td>26.8</td>
<td>0.276</td>
</tr>
<tr>
<td>Complex septated echoic (%)</td>
<td>80.0</td>
<td>4.5</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

RPT, residual pleural thickening.

Table 4 Initial sonographic findings of patients with pure tuberculous pleurisy with RPT &gt;10 mm and &lt;10 mm

<table>
<thead>
<tr>
<th>Sonographic features</th>
<th>RPT &gt;10 mm (n = 14)</th>
<th>RPT &lt;10 mm (n = 51)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anechoic (%)</td>
<td>7.1</td>
<td>72.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Complex non-septated echoic (%)</td>
<td>21.4</td>
<td>21.6</td>
<td>1.0</td>
</tr>
<tr>
<td>Complex septated echoic (%)</td>
<td>71.5</td>
<td>5.9</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

RPT, residual pleural thickening.

After the start of anti-TB treatment (74.3% (9.9%) predicted vs 80.8% (9.3%) predicted, p &lt;0.05; and 75.4% (9.9%) predicted vs 84.0% (18.4%) predicted, p &lt;0.05, respectively).

DISCUSSION

In the present study, we demonstrated the usefulness of sonography in predicting the sequelae of TP after anti-TB treatment. A complex septated pattern shown in the initial sonographic study appears to be a predicting feature for RPT in association with a decreased forced vital capacity.

Dutt et al reported good efficacy of the 6-month regimen of rifampin and isoniazid for TP in 1992, and this regimen has been widely used ever since. Despite effective anti-TB chemotherapy, RPT is considered to be a common radiographic sequelae in patients with TP after treatment. The incidence of RPT levels &gt;10 mm 1 year after the start of anti-TB treatment is about 23% in the present study. RPT may reduce static and dynamic lung volumes and thus have important clinical repercussions. Therefore, clinical and functional impairments induced by RPT are not uncommon in TP patients treated with standard anti-TB drugs.

Regarding the development of RPT after anti-TB treatment, most of the studies measured RPT right at the termination of medication (ie, 6 months after the beginning of anti-TB medication). However, further resolutions of RPT after discontinuance of treatment have been reported. Radiographic improvements of RPT can occur even at 6 months after the completion of anti-TB chemotherapy. Chan et al conducted a retrospective study which assessed 83 patients with TP, 22 of whom had been medically treated 2 years previously. None of them had significant RPT and their pulmonary function tests did not show any significant impairment when compared with matched control subjects. Han et al reported that the incidence of RPT decreased from 50.6% at 6 months to 27.1% at 12 months after the start of medication. These studies indicate that RPT is a common complication of TP and may regress with time. It is possible that RPT in the initial phase is composed of inflammatory tissues which can be decreased by anti-TB treatment. The local inflammatory hypersensitivity response in TP is mediated in part by a number of proinflammatory mediators such as complement-degrading products, interferon γ and cytokines which are abundant in the pleural effusion. As the inflammatory activity was reduced with treatment, the pleural inflammatory cells are decreased and the inflammatory mediators are also decreased.
fibrous tissue within the pleural effusion forms RPT which barely changes with time.

In this study we took 12 months after the start of anti-TB chemotherapy as the evaluation point to determine the possible risk factors. Along with demographic and clinical features, serum and pleural fluid analysis, and initial chest radiographic patterns, the initial sonographic features of TP were used to identify which patients were more likely to develop persistent RPT. Findings in the published literature have been quite controversial with respect to the prediction of RPT. While Barbas et al could not find any association between RPT and demographics or pleural fluid analyses including pleural LDH difference in RPT, Ruit et al analyses except for the level of pleural LDH. Regarding gender present study the development of RPT does not appear to be well correlated with the initial pleural fluid biochemical analyses except for the level of pleural LDH. Regarding gender difference in RPT, Ruit et al found RPT to be more common in males with TP. By univariate analysis, we demonstrated a male predominance of RPT. However, this finding appears to be insignificant by multivariate analysis. By multiple logistic regression analysis, we could only identify TB bacillus in pleural fluid culture and septate complex echo as significant predictors of RPT levels >10 mm.

The value of sonography for evaluation of pleural disease has been well documented. The presence of septation in the pleural fluid revealed by sonography has been shown to be related to the cellular debris in empyema and to clots in the haemothorax. Sonographic septation is also a useful prognostic indicator of acute thoracic empyema. Since TP may be a chronic inflammation followed by a pleural fibrosis process which may result in RPT, patients with complex septated echo patterns were more likely to benefit from intrapleural fibrinolytic therapy. In the present study, 16 of 20 patients with RPT levels >10 mm had a septated complex pattern in the initial sonography. On the other hand, there were only 3 out of 67 patients with RPT levels <10 mm who had the septated complex sonographic patterns. The sensitivity of predicting RPT levels >10 mm for a complex septated sonographic pattern is 84%, with a specificity of 96%, positive predictive value of 84% and negative predictive value of 94%. In patients with pure TB, sonographic septation had a similar predictive value. Therefore, sonographic septation can serve as a useful predictor for the development of RPT after anti-TB treatment.

Akham et al studied 20 patients with TP using ultrasonography, and septations with a lattice-like appearance were found in 6 (30%) patients. In 1989 Martinez et al reported that winding bands were seen with sonography in 8 out of 21 (38%) patients with TP. In the present study we showed that 17 out of 87 (21.8%) patients had septation revealed by thoracic sonography. In a recent study it was shown that early effective drainage with streptokinase for TP may reduce the occurrence of RPT. Therefore, predicting which patients with TP will develop RPT in the long run is crucial. Thus effective drainage with fibrinolytic therapy in addition to standard anti-TB drug treatment should be introduced for such patients. In the present study, we also showed that patients with RPT levels >10 mm had a lower forced vital capacity than those without. Although Candela et al showed a weak correlation between the forced vital capacity and the degree of radiographic pleural thickening at the end of follow-up, only 6% of patients had RPT levels >10 mm in their study, which is much lower than in our series (26%).

There were some limitations to this study. First, we were unable to test pulmonary function prior to the initial presentation of TP. It is possible that the difference in forced vital capacity between the two groups existed before the development of TP. However, it is not feasible to collect details of patients’ pulmonary function before they become infected with TB. Furthermore, since patients with TP have the potential to have pulmonary TB and performing pulmonary function tests might raise concern regarding spreading this infectious disease, we did not check lung function at the very beginning. Another limitation is that pleural thickness was not evaluated at initial presentation of these patients, which may make the correlation of complex TP and RPT weak. However, no obvious pleural thickness had been observed in the initial radiographic studies. In addition, the patients had no previous pleural disease or other major pulmonary disease by history taking.

In conclusion, the results of the present study suggest that severe TP shares some common features with thoracic empyema. A sonographic septated complex echo pattern but not the pleural fluid biochemical analysis is a useful feature to predict RPT levels >10 mm 1 year after the start of anti-TB drug treatment in patients with TP. An RPT level >10 mm was associated with a higher probability of a decreased lung volumes.

Competing interests: None.

Patient consent: Obtained.

Provenance and peer review: Not commissioned; externally peer reviewed.

REFERENCES


Sonographic septation: a predictor of sequelae of tuberculous pleurisy after treatment
Y-F Lai, M-C Su, H-H Weng, J-T Wu and C-T Chiu

Thorax 2009 64: 806-809 originally published online June 3, 2009
doi: 10.1136/thx.2008.110197

Updated information and services can be found at:
http://thorax.bmj.com/content/64/9/806

These include:

References
This article cites 19 articles, 4 of which you can access for free at:
http://thorax.bmj.com/content/64/9/806#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/